Entities / Company
Monte Rosa Therapeutics.
biotechnology company
- Reports this week
- 0
- Active events
- 0
- Connections
- 14
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
-
Monte Rosa Therapeutics and Arvinas, Inc. are listed on Nasdaq, and MarketBeat provided analyst recommendations for both companies.Some support1 report
-
Monte Rosa Therapeutics announced a global license agreement with Novartis and a strategic collaboration with Roche.Well supported6 reports1 development inside
One to three months ago
-
Jefferies Financial Group reissued a 'buy' rating on Monte Rosa Therapeutics, whose stock trades on the Nasdaq exchange.Some support1 report
-
Monte Rosa Therapeutics' stock traded on the Nasdaq exchange, and the company disclosed transactions with the SEC, including an insider sale on June 24th.Some support4 reports1 development inside
Gone quiet
No new reports in 90+ days-
Monte Rosa Therapeutics filed transactions via SEC Form 4 on June 29, involving Chief Medical Officer Filip Janku.Some support1 report
-
Monte Rosa Therapeutics develops molecular glue degrader medicines.Some support1 report1 development inside
-
Monte Rosa Therapeutics published key research insights in the journal Science on July 4, 2025. John Castle served as the Chief Data Officer during this publication.Speculative1 report
No events began in the chosen period. Widen it, or reset.
Around Monte Rosa Therapeutics this week
News at the entities that move Monte Rosa Therapeutics most-
Novartis StructuralNovartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.Moves Monte Rosa Therapeutics
-
Jefferies Financial Group TransactionalApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Monte Rosa Therapeutics
-
SEC StructuralDHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Moves Monte Rosa Therapeutics
-
Nasdaq StructuralAppLovin stock is traded on Nasdaq, and both AppLovin and Trade Desk operate in the competitive digital advertising technology landscape.Moves Monte Rosa Therapeutics
-
MarketBeat Mentioned togetherMarketBeat aggregates data on IDT Corporation stock performance.Moves Monte Rosa Therapeutics
-
Boston Shared contextThe Federal Aviation Administration is managing air traffic operations at Boston Logan Airport.Moves Monte Rosa Therapeutics
Connections
The 7 strongest of 14, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Novartis Structural
Monte Rosa Therapeutics and Novartis maintain a formal, ongoing partnership through global and exclusive licensing agreements for drug development.
-
Jefferies Financial Group Transactional
Jefferies Financial Group issued a 'buy' rating on Monte Rosa Therapeutics.
-
Filip Janku Structural
Filip Janku serves as the Chief Medical Officer of Monte Rosa Therapeutics.
-
SEC Structural
Monte Rosa Therapeutics is subject to mandatory regulatory filing and disclosure requirements enforced by the SEC.
-
Nasdaq Structural
Monte Rosa Therapeutics is a publicly listed company whose trading and existence are governed by the Nasdaq stock exchange.
-
Boston Shared context
Monte Rosa Therapeutics is based in Boston.
-
MarketBeat Mentioned together
MarketBeat provides published analyst recommendations regarding Monte Rosa Therapeutics.
History
Events by the month they beganSeptember 2026
1 eventAugust 2026
1 eventJune 2026
5 events- Monte Rosa Therapeutics announced a global license agreement with Novartis and a strategic collaboration with Roche.
- Monte Rosa Therapeutics' stock traded on the Nasdaq exchange, and the company disclosed transactions with the SEC, including an insider sale on June 24th.
- Monte Rosa Therapeutics filed transactions via SEC Form 4 on June 29, involving Chief Medical Officer Filip Janku.
- Monte Rosa Therapeutics develops molecular glue degrader medicines.
- Monte Rosa Therapeutics published key research insights in the journal Science on July 4, 2025. John Castle served as the Chief Data Officer during this publication.